Targets › DENV2
4 programs from 3 companies in 4 trials: 2 Phase 2, 1 Phase 1, 1 Phase 4; Infectious disease, Immunology; next expected readout Dec 2027.
Open in Phaseline: the race on DENV2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Sao Paulo General Hospital | Dengue 1,2,3,4 (attenuated) vaccine Live attenuated tetravalent dengue vaccine (DENV-1, DENV-3, DENV-4, and chimeric DENV-2) | DENV1, DENV2, DENV3, DENV4 | Phase 4 | Rheumatoid Arthritis (RA) | Dec 2027 |
| Beth Kirkpatrick | TV005 Live attenuated tetravalent dengue vaccine (rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, rDEN4Δ3 | DENV1, DENV2, DENV3, DENV4 | Phase 2 | Dengue | – |
| Beth Kirkpatrick | rDEN2Δ30-7169 attenuated virus strain Live attenuated DENV-2 virus strain with 30 nucleotide deletion in 3' UTR (derived from To | DENV2 | Phase 2 | Dengue | – |
| National Institute of Allergy and Infectious Diseases (NIAID) | rDEN2delta30-7169 Live attenuated dengue virus 2 with 30-nucleotide deletion in 3' UTR | DENV2 | Phase 1 | Healthy Volunteers | Nov 2028 |
Dengue (2) Healthy Volunteers (1) Rheumatoid Arthritis (RA) (1)
mixed (2), protein or peptide (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.